Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 314 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infiltration Clear all
Recruiting Phase 1 Interventional

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

NCT07192900
View directory record Official record
Conditions
Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions
locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2
Biological · Drug
Lead sponsor
David Bartlett, MD
Other
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 7:03 AM EDT
Withdrawn Not applicable Interventional

Lesion Progression of Approximal Caries After Resin Infiltration

NCT02191943
View directory record Official record
Conditions
Proximal Caries
Interventions
Duraphat, Icon approximal caries infiltration kit
Device
Lead sponsor
DMG Dental Material Gesellschaft mbH
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 22, 2026, 7:03 AM EDT
Terminated Phase 3 Interventional Results available

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

NCT02740114
View directory record Official record
Conditions
Malignant Neoplasms of Female Genital Organs, Gynecologic Cancer
Interventions
Bupivacaine, Liposomal Bupivacaine, Oxycodone, Pill Diary, Symptom Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 22, 2026, 7:03 AM EDT
Withdrawn Phase 2 Interventional

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

NCT01100489
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Tubular Ductal Breast Carcinoma
Interventions
external beam radiation therapy, questionnaire administration, therapeutic conventional surgery
Radiation · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Cleveland, Ohio • Orange, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 22, 2026, 7:03 AM EDT
Terminated Phase 1 Interventional

A Study of DeTIL-0255 in Adults With Advanced Malignancies

NCT05107739
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
Interventions
Drug Product De-TIL-0255
Biological
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
New Brunswick, New Jersey • Buffalo, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 22, 2026, 7:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

NCT06940739
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Interventions
IOV-3001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Denver, Colorado • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 22, 2026, 7:03 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

NCT02353754
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine injection, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 22, 2026, 7:03 AM EDT
Completed Phase 2 Interventional

Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia

NCT00054171
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
aminolevulinic acid hydrochloride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 22, 2026, 7:03 AM EDT
Completed No phase listed Observational

Optical Detection of Intravenous Infiltration

NCT01126710
View directory record Official record
Conditions
Intravenous Infiltration, Extravasation of Diagnostic and Therapeutic Materials
Interventions
Not listed
Lead sponsor
CW Optics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 22, 2026, 7:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

NCT01236573
View directory record Official record
Conditions
Skin Cancer, Metastatic Melanoma
Interventions
Fludarabine, Cyclophosphamide, IL-12 transduced TIL
Drug · Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 66 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 22, 2026, 7:03 AM EDT
Completed Phase 1 Interventional

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

NCT05154994
View directory record Official record
Conditions
Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Belinostat, Durvalumab
Drug · Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 7:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT05361174
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
IOV-4001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 7:03 AM EDT
Terminated Not applicable Interventional

Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma

NCT04341740
View directory record Official record
Conditions
Renal Cell Carcinoma, Urothelial Carcinoma
Interventions
Bone Marrow Aspirate
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 22, 2026, 7:03 AM EDT
Terminated Phase 2 Interventional

ITIL-168 in Advanced Melanoma

NCT05050006
View directory record Official record
Conditions
Advanced Cutaneous Melanoma
Interventions
ITIL-168
Biological
Lead sponsor
Instil Bio
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 22, 2026, 7:03 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Can PLIA Reduce Early Post-operative Pain After PAO Surgery?

NCT06519955
View directory record Official record
Conditions
Hip Dysplasia
Interventions
Ropivacaine, Epinephrine, Ketorolac, NaCl (Saline)
Combination Product
Lead sponsor
Michael C Willey
Other
Eligibility
13 Years to 50 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 7:03 AM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

NCT01319565
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 22, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy

NCT04300231
View directory record Official record
Conditions
Cystectomy
Interventions
epidural bupivacaine 0.05%, Liposomal bupivacaine, bupivacaine 0.125%, bupivacaine 0.5%, /hydromorphone 0.05mg/ml, injectable saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 22, 2026, 7:03 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

NCT02621021
View directory record Official record
Conditions
Melanoma
Interventions
young TIL, Pembrolizumab, Aldesleukin, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 7:03 AM EDT
Completed Not applicable Interventional Results available

Radiographic Progression of Infiltrated Caries Lesions In-vivo

NCT01496456
View directory record Official record
Conditions
Dental Caries
Interventions
Resin infiltration, Caries management
Device · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
14 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 22, 2026, 7:03 AM EDT
Completed Phase 4 Interventional Results available

Effects of Adrenaline Infiltration on Surgical Field of View in Endoscopic Sinus Surgery

NCT05867342
View directory record Official record
Conditions
Intraoperative Bleeding
Interventions
Epinephrin, 1% lidocaine with epinephrin 1:100,000, Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 22, 2026, 7:03 AM EDT
Recruiting Phase 2 Interventional

TIL Therapy in cSCC and MCC

NCT07288073
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer
Interventions
LN-145, Cyclophosphamide, Fludarabine, Interleukin-2
Biological · Drug
Lead sponsor
Karam Khaddour, MD, MS
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 22, 2026, 7:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

NCT06237881
View directory record Official record
Conditions
Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
Interventions
KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 7:03 AM EDT
Completed Phase 4 Interventional Results available

TAP-patients With Robotic Assisted Lap Prostatectomy

NCT01582477
View directory record Official record
Conditions
Postsurgical Pain, Analgesia, Prostatectomy
Interventions
EXPAREL 20 mL, EXPAREL 40 mL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 22, 2026, 7:03 AM EDT
Terminated Phase 1 Interventional

ITIL-306 in Advanced Solid Tumors

NCT05397093
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions
ITIL-306
Biological
Lead sponsor
Instil Bio
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 22, 2026, 7:03 AM EDT